Very common side effects (affecting more than 1 in 10 people) include: Nausea, vomiting, and diarrhoea (usually temporary) Reduced appetite Common side effects (affecting up to 1 in 10 people) include: Constipation Abdominal pain or discomfort Headache Injection site reactions Fatigue Contact your GP promptly if you experience: Persistent or severe abdominal pain , particularly if radiating to the backthis may indicate pancreatitis Persistent vomiting that prevents adequate fluid intake Signs of dehydration : reduced urination, dizziness, dry mouth Symptoms of hypoglycaemia (if taking alongside insulin or sulphonylureas): trembling, sweating, confusion, rapid heartbeat Visual changes or eye pain, especially if you have diabetic retinopathy Unexplained weight loss exceeding expected therapeutic effect Mood changes or thoughts of self-harm Right upper abdominal pain, yellowing of skin/eyes, or dark urine which may indicate gallbladder problems Seek immediate medical attention (call 999 or attend A&E) if you develop: Severe, persistent abdominal pain with vomiting Signs of severe allergic reaction: difficulty breathing, facial swelling, severe rash Symptoms of diabetic ketoacidosis (particularly if insulin doses have been reduced): excessive thirst, frequent urination, confusion, fruity breath odour Severe hypoglycaemia with loss of consciousness Important safety information: GLP-1 medications are not recommended during pregnancy or breastfeeding
The resolutions of the final consensus maps were 2.2 , 2.2 , 2.7 and 3.0 for the CTR, AMY 1 R, AMY 2 R and AMY 3 R, respectively, determined at gold standard Fourier shell correlation (FSC) 0.143 (Fig
"But it was the complete opposite
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimers disease
If you are experiencing changes in sexual function while on GLP-1 therapy, schedule a consultation at our Lexington, Louisville, or London, KY location
While the cited articles provide valuable insights, their mechanistic and clinical heterogeneities highlight the need for a more standardized and pathway-centric approach in this field
